Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry
|
October 18, 2007
Mozart's movements and behaviour: a case of Tourette's syndrome?
Aidin Ashoori, Joseph Jankovic
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 13, 2008
Movement disorders in musicians
Joseph Jankovic, Aidin Ashoori
Frontiers in Neurology
|
December 1, 2015
Effects of Auditory Rhythm and Music on Gait Disturbances in Parkinson's Disease
Aidin Ashoori, David M Eagleman, Joseph Jankovic
Journal of Palliative Medicine
|
January 4, 2011
Demographic and clinical determinants of having do not resuscitate orders in the intensive care unit of a comprehensive cancer center
Marylou Cardenas-Turanzas, Susan Gaeta, Aidin Ashoori, et al.
Journal of Neuro-Oncology
|
September 6, 2015
Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients
Amanda Wakefield, Antonella Pignata, Alexia Ghazi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
February 7, 2012
Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma
Alexia Ghazi, Aidin Ashoori, Patrick J Hanley, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
August 14, 2013
Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma
Meenakshi Hegde, Amanda Corder, Kevin K H Chow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2015
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Nabil Ahmed, Vita S Brawley, Meenakshi Hegde, et al.
JAMA Oncology
|
April 21, 2017
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial
Nabil Ahmed, Vita Brawley, Meenakshi Hegde, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Journal of Neurology, Neurosurgery, and Psychiatry
|
October 18, 2007
Mozart's movements and behaviour: a case of Tourette's syndrome?
Aidin Ashoori, Joseph Jankovic
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 13, 2008
Movement disorders in musicians
Joseph Jankovic, Aidin Ashoori
Frontiers in Neurology
|
December 1, 2015
Effects of Auditory Rhythm and Music on Gait Disturbances in Parkinson's Disease
Aidin Ashoori, David M Eagleman, Joseph Jankovic
Journal of Palliative Medicine
|
January 4, 2011
Demographic and clinical determinants of having do not resuscitate orders in the intensive care unit of a comprehensive cancer center
Marylou Cardenas-Turanzas, Susan Gaeta, Aidin Ashoori, et al.
Journal of Neuro-Oncology
|
September 6, 2015
Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients
Amanda Wakefield, Antonella Pignata, Alexia Ghazi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
February 7, 2012
Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma
Alexia Ghazi, Aidin Ashoori, Patrick J Hanley, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
August 14, 2013
Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma
Meenakshi Hegde, Amanda Corder, Kevin K H Chow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2015
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Nabil Ahmed, Vita S Brawley, Meenakshi Hegde, et al.
JAMA Oncology
|
April 21, 2017
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial
Nabil Ahmed, Vita Brawley, Meenakshi Hegde, et al.
Page
of 1